UB386
TargetsAT2R
IndicationsPost-stroke pain
ClinicalCN - II
TherapeuticsNeurology; Anesthesiology
ModalitiesSmall Molecule
Exclusive Summary
- • Highly selective AT2R antagonist with strong preclinical efficacy in neuropathic pain and post-surgical pain.
- • Excellent safety & PK profile in Phase I study.
- • Superior efficacy vs. Dezocin & Flurbiprofen Axetil in minipig surgical pain model.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →